Daiichi Sankyo

Daiichi SankyoThe Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Daiichi Sankyo Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.

Daiichi Sankyo RSS Channel

Title Filter      Display #  
# Article Title
1 Daiichi Sankyo and Ranbaxy launch hybrid business in Brazil to expand business of both companies
2 Daiichi Sankyo Establishes New Vaccine Research Unit in Japan
3 Daiichi Sankyo & Ranbaxy Announce a New Social Contribution Initiative
4 Daiichi Sankyo and Ranbaxy to Integrate New Drug Research and Development System
5 Ranbaxy Launches Antiplatelet Agent Prasugrel in India
6 Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient™
7 DAIICHI SANKYO continues its expansion in Germany and Europe
8 DAIICHI SANKYO acquires osteoporosis medication EVISTA® from Lilly
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]